SUPRIYA LIFESCIENCE ALL AROUND SET TO TAP PHARMA API OPPORTUNITY: MOTILAL OSWAL FINANCIAL SERVICES' SNEHA PODDAR

 

"We like Supriya Lifescience for its specialty item portfolio, in reverse incorporated plan of action and hearty financials. It is very much positioned to tap the chance in the pharma API market given its solid pipeline zeroed in on additional broadening," said Sneha Poddar, AVP-Retail Research at Motilal Oswal Financial Services.

"Supriya Lifescience has a specialty item arrangement of 38 APIs with center basically around different restorative regions. It has reliably been India's biggest exporter of specific specialty items with an even presence among managed and semi/non-directed business sectors," she said.

Supriya Lifescience shares were at Rs 401.4 each on BSE and Rs 400.7 each on NSE around early afternoon. That denoted a premium of in excess of 46% over the issue cost of Rs 274. (Peruse more on Supriya Lifescience shares)


Comments

Popular posts from this blog

RAHUL BAJAJ, AN INDUSTRIALIST, DIED AT THE AGE OF 83

SPACE AGENCY SAYS CHANDRAYAAN-2 ORBITER DETECTS SOLAR PROTON EVENTS ISRO

Sourav Ganguly Tests Positive For Covid, Admitted To Hospital: Report